PR Newswire SAN DIEGO, Nov. 7, 2024 SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the ...
PR Newswire PLYMOUTH MEETING, Pa., Nov. 7, 2024 National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...
PR Newswire HOUSTON, Nov. 7, 2024 - CK0804 is an off-the-shelf, allogeneic, non-HLA matched, CXCR4 enriched, T regulatory cell therapy product.- Multiple doses of CK0804 can be safely infused in myelofibrosis patients- CK0804 reduces ...
PR Newswire NEW YORK, Nov. 7, 2024 Publication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK, ...
Canada NewsWire TORONTO, Nov. 6, 2024 Informing and empowering people impacted by CML, a once-fatal blood cancer now a manageable disease TORONTO, Nov. 6, 2024 /CNW/ - Every year, approximately 700 Canadians are diagnosed with chronic ...
PR Newswire SAN JOSE, Calif., Nov. 6, 2024 SAN JOSE, Calif., Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
PR Newswire IRVING, Texas, Nov. 6, 2024 MI Cancer Seek is the first and only simultaneous Whole Exome and Whole Transcriptome-based assay with CDx indications for adults and pediatric patients IRVING, Texas, Nov. 6, 2024 /PRNewswire/ -- ...
PR Newswire SHANGHAI, Nov. 6, 2024 SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today announced initial ...
PR Newswire NANJING, China, Nov. 6, 2024 NANJING, China, Nov. 6, 2024 /PRNewswire/ -- On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging ...
PR Newswire COVINGTON, Ky., Nov. 5, 2024 COVINGTON, Ky., Nov. 5, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and ...
Immunotherapy is a promising treatment that harnesses the immune system to combat cancer, but its effectiveness has been limited in treating gastrointestinal cancers. ...
Adding immunotherapy to neoadjuvant chemoradiation can improve survival and enable surgery in esophageal cancer, reveals research results published in a journal of the American Association for Cancer Research. Bottom Line In patients with unresectable, locally advanced esophageal cancer, the combination of radiation, chemotherapy, and immunotherapy increased the likelihood of tumors becoming surgically removable, leading to significantly better ...
A small clinical trial has shown encouraging outcomes for patients with triple-negative breast cancer who were treated with an experimental vaccine aimed at preventing tumor...
Cannabis consumption can wreak havoc on our cellular health, significantly increasing the risk of developing deadly cancerous tumors. In the study, published in the scientific journal Addiction Biology, cannabis is described as a ...
An investigational white button mushroom supplement shows promise in slowing and even preventing the spread of prostate cancer among men participating in a phase 2 clinical trial exploring food as medicine , suggests a new study led by a team ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers